Tag Archives: Cancer Treatment

The Keto Diet May Prove Beneficial to Cancer Patients While in Treatment

What You Put in Your Body Could Be Affecting Your Likelihood of Catching Cancer.
What You Put in Your Body Could Be Affecting Your Likelihood of Catching Cancer.

People are always looking for the next great diet in an effort to lose weight. The recently popular ketogenic diet could have some surprising benefits for patients undergoing cancer treatment.

The Warburg Effect

Cancer cells proliferate via the Warburg effect, named for the scientist who first advanced the idea. Fermentation is a process by which sugars are metabolized to provide energy for bacteria. Sauerkraut and yogurt are some of the more widely-known products of fermentation.

Unlike normal body cells, which derive their energy from mitochondria, cancer cells receive energy from fermentation of glucose within cytoplasm. When a cell starts getting energy from glucose, it can be the first sign of abnormal cell function that ultimately results in formation of a tumor.

The Ketogenic Diet: Starving Cancer Cells

A keto diet plan is low in carbohydrates and high in fat. The science behind it is based on a biological response that dates back to prehistoric times. When food was scarce, the body responded by shifting metabolic gears and using stored fat as fuel.

When the body’s supply of carbs is restricted, it shuts off the flow of glucose and other cancer-promoting fuels. As cancer cells become compromised, the body resumes its normal cellular signaling, putting the brakes on further tumor development.

The keto diet should not be considered a cure for cancer. However, it’s a valuable tool for use in conjunction with immunotherapy and other cancer treatment.

Immunotherapy and Nutrition: A Winning Combination

Good nutrition is a perfect complement for our non-toxic cancer treatment programs. Visit our website for more information about cancer vaccines and other individually created treatments.

Ribosomes May be Hijacked to Protein Fuel for Cancers

It's Time to Stop Cancer
It’s Time to Stop Cancer

Cancer cells often have an uncanny ability to hijack the functions of normal body cells. Scientists have focused on this property in the belief that deciphering the process will lead to more effective cancer treatment.

Thanks to the results of a Yale University study, the scientific community may be a little closer to this goal. Discovery of unknown pathways to fuel sources provides insights into the development and growth of cancer.

How Cell Proteins Drive Cancer Growth

Organelles are specialized structures in cells that carry out certain tasks, much like organs do for the human body. One of these organelles, called the nucleolus, produces ribosomes, which in turn manufacture proteins.

Ribosomes can be hijacked by cancer cells to divert protein production in order to fuel cancer growth. In a study published in Cell Reports, Dr. Susan Baserga of Yale University and two of her graduate students screened 18,000 proteins that are vital to nucleoli formation.

A Target for Immunotherapy Cancer Treatment?

Dr. Baserga and her team found 139 proteins that serve as a type of master switching network. The proteins represent countless cellular pathways that control the production of ribosomes. This discovery clarifies the link between ribosomes and cancer as well as the one between ribosomes and certain birth defects known as ribosomopathies.

Personalized Cancer Treatment at Issels®

Our innovative cancer treatments target both the tumor and its microenvironment. Immunotherapy programs at Issels® are created specifically to address a patient’s individual needs.

Contact us to learn how our effective cancer treatments have helped patients whose advanced cancers were non-responsive to traditional therapies.

Liquid Biopsy Test for Cancer Has Problematic Accuracy Results

Liquid Biopsy Test for Cancer Has Problematic Accuracy Results
Liquid Biopsy Test for Cancer Has Problematic Accuracy Results

Early detection improves the chances of successful cancer treatment, so recent news of a “liquid biopsy” has encouraged the medical community. Unfortunately, the test is showing unacceptable levels of accuracy, leaving the procedure a long way from any real-world applications.

Controlled vs. Real World Conditions

CancerSEEK uses a blood sample for a battery of tests to measure tumor biomarkers and identify cancer-associated DNA mutations. During clinical studies, researchers obtained some promising results.

By the team’s own admission, the conditions were optimized to facilitate detection of cancer. Even so, most of the cancers detected were late-stage while the goal of screening was to find cancer in the early stages.

Accuracy problems in less-controlled environments became more clear in a 2017 study involving 40 prostate cancer patients who underwent liquid biopsies to fine-tune their therapy programs. Each sample was sent to two different labs with similar technology, but the results differed for more than half of the patients.

Are Liquid Biopsies the Answer?

Researchers are also questioning the full value of a positive result. While the test may detect the presence of cancer, it gives no clues as to the location of the tumor, unlike traditional screenings such as mammograms and CT scans.

Scientists will no doubt continue to study the science behind liquid biopsies, as detection of circulating tumor DNA can have other applications. The question remains whether liquid biopsies have a viable future as useful cancer screening.

Personalized Cancer Treatment at Issels®

We use a variety of specialized non-invasive standard and genomic diagnostic tests to create the cancer treatment that’s right for you. Contact us for more information.

Research Studies Now Under Way to Starve Cancer Tumors

Research Studies Now Under Way to Starve Cancer Tumors
Research Studies Now Under Way to Starve Cancer Tumors

According to a popular old wives’ tale, you should starve a cold and feed a fever. Scientists working on immunotherapy for cancer are taking that advice a step further as they develop a new treatment that “starves” tumors to death.

Cutting Off Cancer’s Fuel Source

Glutamine is an amino acid found throughout the body, with the largest concentrations in blood and bone. While glutamine plays a major role in cellular synthesis of proteins, it also provides fuel for the rapid cell division of many types of cancer.

A research team at Vanderbilt University in Nashville began exploring the idea of blocking glutamine from cancer cells as a possible form of treatment. They focused on ASCT2, a protein that transports glutamine to cancer cells as well as other parts of the body.

The scientists created an ASCT2 inhibitor called V-9302. In testing on both mice and cancer cells developed in vitro, V-9302 was able to stop tumor growth by increasing oxidative stress on cancer cells, leaving them to eventually die off.

Using PET Imaging to Trace Tumors

As the team noted in their report, the next step is to find a way to determine how effective the inhibitors are in restricting glutamine access. The researchers suggested using positron emission tomagraphy (PET) scans to spot increases in glutamine metabolic rates.

Individually Created Immunotherapy for Cancer at Issels®

Not all cancer patients respond to treatment the same way. That’s why our immunotherapy for cancer programs are designed to address each patient’s unique case. Contact us to learn more about Issels® and our track record of helping patients achieve long-term remission.

Swiss Group Studies Dendritic Cell Vaccines with Artificial Receptors

New Cancer Research Is Improving Treatment
New Cancer Research Is Improving Treatment

One of the challenges doctors face with cancer treatment is designing a program to meet a patient’s unique needs. Immunotherapy for cancer is helping to provide solutions to this problem, such as recent improvements to dendritic cell vaccines.

Immunotherapy: Priming the Body’s Immune System

While the body’s immune system is extremely capable when it comes to fighting viruses, bacteria and other invaders, cancer cells often demonstrate a remarkable ability to evade detection. Immunotherapy works by enhancing the immune system’s power to target and destroy cancer cells.

Dendritic cells are one of the immune system’s “messengers” that present antigens to killer T-cells for destruction. Researchers in Switzerland began looking for a way to improve the effectiveness of dendritic cell vaccines.

Helping the Immune System Recognize Cancer Cells

Prof. Michele De Palma and his team created artificial receptors known as EVIRs, which are inserted in dendritic cells extracted from a patient. Once reintroduced into the patient’s system, the EVIRs are engineered to recognize exosomes that transport molecules between cells, sometimes assisting in the spread of cancer.

As EVIRs capture exosomes, it allows dendritic cells to present antigens on their outer surface, simplifying recognition and attack by killer T-cells. De Palma and his team have dubbed this phenomenon “cross-dressing,” and they’re hoping that the process will improve the specificity of cancer treatment.

Issels®: A Successful Legacy of Immunotherapy for Cancer

At Issels®, we are exclusively focused on immunotherapy for cancer with patients who have advanced or therapy-resistant cancers. Contact us to learn more about our dendritic cell vaccines and other non-toxic, personally tailored immunotherapy treatment programs.

New Understanding of High-Risk Neuroblastoma from Massachusetts Research

Issels the Premier Provider of Immuno Oncology
Issels the Premier Provider of Immuno Oncology

Neuroblastoma is a cancer of the sympathetic nervous system that affects primarily infants and children. Thanks to a Massachusetts-based research team, there is now more information about the growth of neuroblastoma that will aid the development of more effective cancer treatment.

“Hijacking” Healthy Cells

Neuroblastoma gets its name from neuroblasts, which are immature cells where this form of cancer develops. For this study, researchers focused on MYCN and c-MYC, two related proteins that have been linked to neuroblastoma’s progression.

In studying tumors from 123 neuroblastoma patients, the team discovered that 25 percent had MYCN applications and another 10 percent showed overexpression of c-MYC. While the groups didn’t overlap, both showed similarly poor survival rates.

Scientists then conducted a study with zebrafish and determined that c-MYC is a more powerful oncogene (a gene that has the potential to turn a normal cell cancerous) than MYCN, Results showed that c-MYC overexpression has a greater chance of creating neuroblastoma along with a shorter onset time.

Debut of 3D Genomics

Another exciting aspect of this study is that it was the first use of 3D genomics. A technology known as Hi-C, or in situ chromosome conformation capture, helps researchers study genomic interactions to identify abnormalities.

Since c-MYC can be detected in the clinic, scientists are hoping that they’ll eventually be able to develop a new cancer treatment that targets and degrades the protein.

Personally Tailored Cancer Treatment Programs from Issels®

Just as all people are individuals, so too are all cases of cancer different. We use targeted therapies and other treatments to address the specific needs of each patient. Contact us for more information.